Antiviral therapy and prevention against hantavirus infections

被引:11
|
作者
Szabo, R. [1 ,2 ,3 ]
机构
[1] Slovak Acad Sci, Biomed Res Ctr, Inst Virol, Dubravska Cesta 9, Bratislava 84505, Slovakia
[2] Comenius Univ, Fac Nat Sci, Bratislava, Slovakia
[3] Univ Cagliari, Dept Biomed Sci, Monserrato, CA, Italy
关键词
hantavirus; HFRS; HCPS; antiviral drugs; vaccines; HUMAN-IMMUNODEFICIENCY-VIRUS; HANTAAN VIRUS; HEMORRHAGIC-FEVER; IN-VITRO; CARDIOPULMONARY SYNDROME; INTRAVENOUS RIBAVIRIN; DOUBLE-BLIND; PULMONARY SYNDROME; ERROR CATASTROPHE; BROAD-SPECTRUM;
D O I
10.4149/av_2017_01_3
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Hantaviruses are emerging zoonoses hosted by small mammals. In humans, they cause two diseases. Hemorrhagic fever with renal syndrome is mainly caused by Dobrava-Belgrade virus, Puumala virus, Seoul virus and Hantaan virus in Asia and Europe. On the other hand, the most important causes of hantavirus cardiopulmonary syndrome are Sin Nombre virus and Andes virus in Americas. Ribavirin yet remains the only licensed drug against the hantavirus infections, but its sufficient antiviral activity remains an issue under discussion. There are still no available vaccines against hantaviruses except of some inactivated virus vaccines licensed only in East-Asian countries. Some of the vaccines are under development in pre-clinical stages. The review discuses about specific compounds with approved antiviral activity against hantaviruses. Other approaches such as development of vaccines, are compiled as well.
引用
收藏
页码:3 / 12
页数:10
相关论文
共 50 条
  • [1] Human hantavirus infections: epidemiology, clinical features, pathogenesis and immunology
    Manigold, Tobias
    Vial, Pablo
    SWISS MEDICAL WEEKLY, 2014, 144
  • [2] Hantavirus Infections-Treatment and Prevention
    Dheerasekara, Kalpa
    Sumathipala, Saranga
    Muthugala, Rohitha
    CURRENT TREATMENT OPTIONS IN INFECTIOUS DISEASES, 2020, 12 (04) : 410 - 421
  • [3] Chloroquine, an Anti-Malaria Drug as Effective Prevention for Hantavirus Infections
    Vergote, Valentijn
    Laenen, Lies
    Mols, Raf
    Augustijns, Patrick
    Van Ranst, Marc
    Maes, Piet
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11
  • [4] Hantavirus infections
    Avsic-Zupanc, T.
    Saksida, A.
    Korva, M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2019, 21 : E6 - E16
  • [5] Hantavirus infections and their prevention
    Krüger, DH
    Ulrich, R
    Lundkvist, Å
    MICROBES AND INFECTION, 2001, 3 (13) : 1129 - 1144
  • [6] Antiviral Efficacy of Favipiravir against Two Prominent Etiological Agents of Hantavirus Pulmonary Syndrome
    Safronetz, David
    Falzarano, Darryl
    Scott, Dana P.
    Furuta, Yousuke
    Feldmann, Heinz
    Gowen, Brian B.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (10) : 4673 - 4680
  • [7] Antiviral Effect of Human Saliva Against Hantavirus
    Hardestam, Jonas
    Petterson, Lisa
    Ahlm, Clas
    Evander, Magnus
    Lundkvist, Ake
    Klingstrom, Jonas
    JOURNAL OF MEDICAL VIROLOGY, 2008, 80 (12) : 2122 - 2126
  • [8] Prognostic Factors in Hantavirus Infections
    Kaya, Selcuk
    MIKROBIYOLOJI BULTENI, 2014, 48 (01): : 179 - 187
  • [9] Hantavirus Infections—Treatment and Prevention
    Kalpa Dheerasekara
    Saranga Sumathipala
    Rohitha Muthugala
    Current Treatment Options in Infectious Diseases, 2020, 12 : 410 - 421
  • [10] Hantavirus infections for the clinician: From case presentation to diagnosis and treatment
    Sargianou, Maria
    Watson, Dionysios Christos
    Chra, Paraskevi
    Papa, Anna
    Starakis, Ioannis
    Gogos, Charalambos
    Panos, George
    CRITICAL REVIEWS IN MICROBIOLOGY, 2012, 38 (04) : 317 - 329